Cargando…

The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients

Clinical importance of time length from initiation under treat-to-target (T2T) strategy to acquisition of clinical remission (TL) in treating patients with rheumatoid arthritis (RA) on disease activity control, daily activities, and quality of life maintenance was investigated. In patients who achie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshii, Ichiro, Chijiwa, Tatsumi, Sawada, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457332/
https://www.ncbi.nlm.nih.gov/pubmed/37626142
http://dx.doi.org/10.1038/s41598-023-39711-4
_version_ 1785096899125051392
author Yoshii, Ichiro
Chijiwa, Tatsumi
Sawada, Naoya
author_facet Yoshii, Ichiro
Chijiwa, Tatsumi
Sawada, Naoya
author_sort Yoshii, Ichiro
collection PubMed
description Clinical importance of time length from initiation under treat-to-target (T2T) strategy to acquisition of clinical remission (TL) in treating patients with rheumatoid arthritis (RA) on disease activity control, daily activities, and quality of life maintenance was investigated. In patients who achieved Boolean remission once or more, relationship between TL and patients’ background data at initiation, and relationship between TL and mean simplified disease activity score (SDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) score, pain score with visual analog scale (PS-VAS), Sharp/van der Heijde Score (SHS) and quality of life score (QOLS) at the first remission and thereafter were evaluated statistically. Patients were divided into two groups whether TL was within 6 months or longer (G ≤ 6 and G > 6). Change of the parameters and Boolean remission rate (BRR) after the first remission between the two groups were compared statistically. In 465 patients, TL correlated significantly with the SDAI score, the HAQ score, PS-VAS, SHS, and the QOLS after the remission. The SDAI score and the BRR after the remission were significantly better in the G ≤ 6 than in the G > 6. TL is an important key to guarantee good and stable clinical course in treating under T2T.
format Online
Article
Text
id pubmed-10457332
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104573322023-08-27 The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients Yoshii, Ichiro Chijiwa, Tatsumi Sawada, Naoya Sci Rep Article Clinical importance of time length from initiation under treat-to-target (T2T) strategy to acquisition of clinical remission (TL) in treating patients with rheumatoid arthritis (RA) on disease activity control, daily activities, and quality of life maintenance was investigated. In patients who achieved Boolean remission once or more, relationship between TL and patients’ background data at initiation, and relationship between TL and mean simplified disease activity score (SDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) score, pain score with visual analog scale (PS-VAS), Sharp/van der Heijde Score (SHS) and quality of life score (QOLS) at the first remission and thereafter were evaluated statistically. Patients were divided into two groups whether TL was within 6 months or longer (G ≤ 6 and G > 6). Change of the parameters and Boolean remission rate (BRR) after the first remission between the two groups were compared statistically. In 465 patients, TL correlated significantly with the SDAI score, the HAQ score, PS-VAS, SHS, and the QOLS after the remission. The SDAI score and the BRR after the remission were significantly better in the G ≤ 6 than in the G > 6. TL is an important key to guarantee good and stable clinical course in treating under T2T. Nature Publishing Group UK 2023-08-25 /pmc/articles/PMC10457332/ /pubmed/37626142 http://dx.doi.org/10.1038/s41598-023-39711-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yoshii, Ichiro
Chijiwa, Tatsumi
Sawada, Naoya
The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
title The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
title_full The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
title_fullStr The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
title_full_unstemmed The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
title_short The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
title_sort impact of time length to boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457332/
https://www.ncbi.nlm.nih.gov/pubmed/37626142
http://dx.doi.org/10.1038/s41598-023-39711-4
work_keys_str_mv AT yoshiiichiro theimpactoftimelengthtobooleanremissionfortightdiseaseactivitycontrolafteracquisitioninrheumatoidarthritispatients
AT chijiwatatsumi theimpactoftimelengthtobooleanremissionfortightdiseaseactivitycontrolafteracquisitioninrheumatoidarthritispatients
AT sawadanaoya theimpactoftimelengthtobooleanremissionfortightdiseaseactivitycontrolafteracquisitioninrheumatoidarthritispatients
AT yoshiiichiro impactoftimelengthtobooleanremissionfortightdiseaseactivitycontrolafteracquisitioninrheumatoidarthritispatients
AT chijiwatatsumi impactoftimelengthtobooleanremissionfortightdiseaseactivitycontrolafteracquisitioninrheumatoidarthritispatients
AT sawadanaoya impactoftimelengthtobooleanremissionfortightdiseaseactivitycontrolafteracquisitioninrheumatoidarthritispatients